期刊文献+

STAT1对人肾透明细胞癌放射敏感性的影响 被引量:1

Effect of STAT1 on radiosensitivity of renal clear cell carcinoma
原文传递
导出
摘要 目的研究人肾透明细胞癌信号传递和转录活化因子1(STAT1)表达情况及抑制STAT1对该肿瘤细胞放射敏感性的影响。方法采用免疫组织化学染色技术对比检测34例人肾透明细胞癌标本和12例正常肾组织标本的STAT1表达。用Western blotting法检测离体培养人肾透明细胞癌细胞(CRL-1932)、纤维母细胞(CCL-116)和Wilm’s瘤细胞(CRL-1441)的STAT1表达。用氟达拉滨和siRNA抑制CRL-1932细胞STAT1表达,并通过成克隆法和台盼蓝染色计数法研究抑制STAT1对CRL-1932细胞放射敏感性的影响。结果人肾透明细胞癌标本的总STAT1和磷酸化STAT1表达均明显高于正常肾组织。Western blotting法显示CRL-1932细胞STAT1表达比CRL-1441、CCL-116细胞明显增高;药物氟达拉滨能显著抑制CRL-1932细胞磷酸化STAT1的表达,并显著增加CRL-1932细胞的放射敏感性,且放射增敏程度与药物浓度呈正相关。经STAT1 siRNA处理后CRL-1932细胞总STAT1和磷酸化STAT1的表达均被有效抑制,且细胞在照射后的存活分数显著下降。结论肾透明细胞癌STAT1呈高表达,抑制STATI对该细胞有放射增敏作用。 Objective To study the expression of signal transducer and activator of transcription 1 (STAT1) in human renal clear cell carcinoma (RCC) and the effect of STAT1 inhibition on the radiosensitivity of RCC. Methods The expression of STAT1 in 34 human RCC samples compared with 12 normal kidney tissues was examined by immunohistochemistry method. For in vitro experiments, a human RCC cell line, CRL-1932, was used. Western blotting was performed to evaluate the expression of total and phosporylated STAT1. Fludarabine and siRNA were respectively used to inhibit the expression of STAT1 in CRL-1932 ceils. Clonogenic assay and trypan blue staining assay were used to evaluate the radiosensitivity of CRL-1932 cells. Results The expression of both total and phosphorylated STAT1 in human RCC samples was significantly higher when compared to normal kidney tissues. Similarly, the expression of STAT1 was higher in CRL-1932 cells when compared to fibroblast and Wilm's tumor cell lines. STAT1 expression was inhibited by both fludarabine and siRNA. Radiosensitivity of CRL-1932 cells was enhanced by both fludarabine and siRNA induced STAT1 inhibition. Conclusions STAT1 is over-expressed in both human RCC tissue and cell line. Inhibition of STAT1 can enhance the radiosensitivity of RCC cells.
出处 《中华放射肿瘤学杂志》 CSCD 北大核心 2009年第3期238-242,共5页 Chinese Journal of Radiation Oncology
基金 国家自然科学基金青年基金项目(30800280)
关键词 细胞系 肾肿瘤 照射 信号传递和转录活化因子 放射增敏剂 Cell line, kidney neoplasms Irradiation Signal transducer and activator of transcription Radiosenstization agent
  • 相关文献

参考文献10

  • 1惠周光,朱晓虹,麦伟源,Teh Bin,Teh Bin Sing.氟达拉滨抑制STAT1表达对乳头状细胞癌放射敏感性的影响[J].中华放射肿瘤学杂志,2008,17(5):344-348. 被引量:1
  • 2Safran H, Dipertrillo T, Akerman P, et al. Phase I / II study of trastuzumab, paelitaxel, cisplatin and radiation for locally advanced, HER2 overexpressing, esophageal adenocarcinoma. Int J Radiat Oneol Biol Phys,2007 ,67 :405-409.
  • 3Bonner JA, Harari PM, Girah J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med ,2006,354:567-578.
  • 4Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjurant chemotherapy for operable HER2-positive breast cancer. N Engl J Med,2005 ,353 :1673-1684.
  • 5Piccart-Gebhart M J, Procter M, Leyland-Jones B, et al. Herceptin adjuvant (HERA) trial study team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med, 2005,353 : 1659-1672.
  • 6Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small cell lung cancer (INTEREST) : a randomised phase Ⅲ trial. Lancet,2008,372 : 1809-1818.
  • 7Kim HS, Lee MS. STAT1 as a key modulator of cell death. Cell Signal ,2007,19:454-465.
  • 8Khodarev NN, Beckett M, Labay E, et al. STAT1 is overexpressed in tumors selected for radioresistance and confer protection from radiation in transduced sensitive cells. Proc Natl Acad Sci USA,2004,101:1714-1719.
  • 9Kita K, Sugaya S, Zhai L, et al. Involvement of LEU13 in interreran-induced refractoriness of human RSa cells to cell killing by X-rays, Radiat Res,2003,160:302-308.
  • 10Fryknas M, Dhar S, Oberg F, et al. STAT1 signaling is associated with acquired crossresistance to doxorubicin and radiation in myeloma cell lines. Int J Cancer,2007,120:189-195.

二级参考文献24

  • 1Haas-Kogan DA, Kogan SS, Yount G, et al. p53 function influences the effect of fractionated radiotherapy on glioblastoma tumors. Int J Radiat Oncol Biol Phys,1999,43:399-403.
  • 2Safran H, Dipetrillo T, Akerman P, et al. Phase Ⅰ / Ⅱ study of trastuzumab, paclitaxel, cisplatin and radiation for locally advanced, HER2 overexpressing, esophageal adenocarcinoma. Int J Radiat Oncol Biol Phys ,2007,67:405-409.
  • 3Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med, 2006,354:567-578.
  • 4Romond EH,Perez EA,Bryant J,et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med ,2005,353 : 1673-1684.
  • 5Piccart-Gebhart M J, Procter M,Leyland-Jones B, et al. Herceptin adjuvant (HERA) trial study team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med, 2005,353 : 1659-1672.
  • 6Amorino GP, Hamilton VM, Valefie K, et al. Epidermal growth factor receptor dependence of radiation-induced transcription factor activation in human breast carcinoma cells. Mol Biol Cell, 2002, 13 : 2233-2244.
  • 7Frank DA, Mahajan S, Ritz J. Fludarabine-induced immunosuppression is associated with inhibition of STAT1 signaling. Nature Med, 1999,5:444-447.
  • 8Buettner R, Mora LB, Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res,2002,8:945-954.
  • 9Tsai MH, Cook JA, Chandramouli GV, et al. Gene expression profiling of breast, prostate, and glioma cells following single versus fractionated doses of radiation. Cancer Res,2007,67:3845-3852.
  • 10Legrand A, Vadrot N,Lardeux B, et al. Study of the effects of interferon a on several human hepatoma cell lines: analysis of the signalling pathway of the cytokine and of its effects on apoptosis and cell proliferation. Liver Int,2004,24 : 149-160.

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部